Advertisement
DALLAS, May 29, 2015 /PRNewswire-iReach/ -- The report "Neisseria Meningitidis Infections – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Neisseria Meningitidis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Meningitidis Infections and special features on late-stage and discontinued projects.
Photo - http://photos.prnewswire.com/prnh/20150529/219364
Meningococcal disease is caused by the bacterium Neisseria meningitides. About 10% of people have this type of bacteria in the back of their nose and throat with no signs or symptoms of disease. Meningococcal disease is a contagious infection spread by close contact with an infected person. The clinical picture of meningococcal disease varies and may include the following Headache, Fever, Vomiting, Photophobia, Lethargy, Neck stiffness, Rash, Seizures etc.
Companies discussed in this Neisseria Meningitidis Infections – Pipeline Review, H1 2015 report include:
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
More reports on Infectious Diseases Therapeutics
Measles – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Beijing Tiantan Biological Products Co., Ltd., Biological E. Limited, China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Serum Institute of India Limited, Universal Stabilization Technologies, Inc., Vical Incorporated, Zydus Cadila Healthcare Limited.
Shigella Infections (Shigellosis) – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis). The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects. Companies discussed in this report include Anacor Pharmaceuticals, Inc., GlaxoSmithKline plc, GlycoVaxyn AG.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnRMarketResearch
Advertisement
Photo - http://photos.prnewswire.com/prnh/20150529/219364
Meningococcal disease is caused by the bacterium Neisseria meningitides. About 10% of people have this type of bacteria in the back of their nose and throat with no signs or symptoms of disease. Meningococcal disease is a contagious infection spread by close contact with an infected person. The clinical picture of meningococcal disease varies and may include the following Headache, Fever, Vomiting, Photophobia, Lethargy, Neck stiffness, Rash, Seizures etc.
Companies discussed in this Neisseria Meningitidis Infections – Pipeline Review, H1 2015 report include:
- ImmunoBiology Ltd.
- MGB Biopharma Limited
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neisseria Meningitidis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neisseria Meningitidis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
More reports on Infectious Diseases Therapeutics
Measles – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Beijing Tiantan Biological Products Co., Ltd., Biological E. Limited, China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Serum Institute of India Limited, Universal Stabilization Technologies, Inc., Vical Incorporated, Zydus Cadila Healthcare Limited.
Shigella Infections (Shigellosis) – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis). The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects. Companies discussed in this report include Anacor Pharmaceuticals, Inc., GlaxoSmithKline plc, GlycoVaxyn AG.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnRMarketResearch
